RxDoctor Payments Data

Justin Ezell, DO

Family Medicine · Fort Worth, TXNPI 1740332212

Payments from drug & device makers

$7,193in general payments, 2019–2025

Across 312 payments — averaging $23.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biohaven Pharmaceuticals, Inc.$1K
  • AbbVie$857
  • Lilly USA, LLC$590
  • Novo Nordisk$507
  • Abbott$479
  • AstraZeneca$453
  • plus $3K from 37 others

What the payments were for

  • Consulting fees$1,20017%
  • Food & beverage$5,99383%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,193 in reported general payments places this provider in the 90th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$80,601
Medicare patients
170
Services billed
1,978

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide116$182,839
FarxigaDapagliflozin Propanediol62$78,447
EliquisApixaban42$61,742
JardianceEmpagliflozin47$60,595
MounjaroTirzepatide30$53,798
Trelegy ElliptaFluticasone/Umeclidin/Vilanter32$44,781
LinzessLinaclotide25$25,720
Tresiba Flextouch U-200Insulin Degludec15$22,332
XareltoRivaroxaban14$20,975
Breztri AerosphereBudesonide/Glycopyr/Formoterol16$17,203
TrulicityDulaglutide12$14,984
MyrbetriqMirabegron11$8,218
Atorvastatin Calcium446$4,693
SymbicortBudesonide/Formoterol Fumarate15$4,084
Tizanidine Hcl92$3,865

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$507$182,839116 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$453$99,73493 claims
Lilly USA, LLCMounjaro, Trulicity$590$68,78242 claims
PfizerEliquis, Prempro$321$64,80455 claims
Boehringer IngelheimJardiance$313$60,59547 claims
GSKTrelegy Ellipta$327$44,78132 claims
AbbVieLinzess$857$25,72025 claims
Johnson & JohnsonXarelto$62$20,97514 claims
Astellas Pharma US IncMyrbetriq$135$8,21811 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Fort Worth

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →